Sugi Predict

Sugi Predict / Compounds / SCHEMBL167426

SCHEMBL167426

SCHEMBL167426

COC(=O)c1ccc(C(F)(F)F)cc1C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 1/20 0.71
▸ CES2 O00748 2/20 0.49
▸ KDM4E B2RXH2 3/20 0.47
▸ ALDH1A1 P00352 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ HSD17B10 Q99714 3/20 0.47
▸ RXRA P19793 1/20 0.47
▸ RXRB P28702 1/20 0.47
▸ USP2 O75604 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ NOTUM Q6P988 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ GLA P06280 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ CASP7 P55210 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ TAS2R14 Q9NYV8 1/20 0.46
▸ MRGPRX4 Q96LA9 1/20 0.45
▸ CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270134 0.89 CFTR (0.57) CFTRKDM4EALDH1A1RXRARXRB
SCHEMBL3943371 0.88 CFTR (0.64) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL22263091 0.87 CFTR (0.73) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL3133633 0.86 CFTR (0.54) CFTRKDM4EALDH1A1HPGDHSD17B10
SCHEMBL28016064 0.84 CFTR (0.51) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL694388 0.84 CFTR (0.69) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL2002005 0.84 CFTR (0.69) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL422201 0.84 CFTR (0.69) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL28172968 0.84 CFTR (0.69) CFTRCES2KDM4EALDH1A1HPGD
SCHEMBL2892428 0.84 CFTR (0.50) CFTRKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137158-A1 DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 — — US disclosed
EP-4540240-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME Monte Rosa Therapeutics AG (CH) 2025-04-23 — — EP disclosed
CN-116003309-B Hydrazide compound, preparation method and application thereof 深圳微芯生物科技股份有限公司 2025-03-04 — — CN disclosed
WO-2023244815-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS, INC. (US) 2023-12-21 — — WO disclosed
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 — — US disclosed
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS TENVIE THERAPEUTICS, INC. 2023-11-09 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
EP-4196125-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2023-06-21 — — EP disclosed
CN-116261456-A Compounds, compositions, and methods 戴纳立制药公司 2023-06-13 — — CN disclosed
US-7326721-B2 Doxepin analogs and methods of use thereof HYPNION, INC. (US) 2008-02-05 — — US disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 — — US disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 — — US disclosed
US-20070191423-A1 Isoquinoline derivatives MERCK PATENT GMBH (DE) 2007-08-16 — — US disclosed
US-20070191423-A1 Isoquinoline derivatives MERCK PATENT GMBH (DE) 2007-08-16 — — US disclosed
US-20070191444-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-08-16 — — US disclosed
US-20070191444-A1 Benzimidazolyl derivatives MERCK PATENT GMBH (DE) 2007-08-16 — — US disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 — — US disclosed
US-7189757-B2 Treatment of sleep disorders using CNS target modulators HYPNION, INC. (US) 2007-03-13 — — US disclosed
US-20050054637-A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof PASCAL ENGINEERING CORPORATION (JP) 2005-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B CFTR 564/4885CES2 3403/4885KDM4E 3777/4885
US-20070191444-A1 Benzimidazolyl derivatives JAK1, MARK1, RAF1 CFTR 382/4885CES2 4558/4885KDM4E 1022/4885
US-20230357162-A1 COMPOUNDS, COMPOSITIONS AND METHODS NLRP3, NLRP1, NOD1 CFTR 905/4885CES2 2870/4885KDM4E 3928/4885
US-20070191423-A1 Isoquinoline derivatives ABL1, MAP3K1, MAP3K2 CFTR 1266/4885CES2 2534/4885KDM4E 1691/4885
US-20050054637-A1 Substituted piperazine cyclohexane carboxilic acid amides and the use thereof AADAC, HCAR2, EGLN2 CFTR 622/4885CES2 66/4885KDM4E 1793/4885
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 CFTR 4669/4885CES2 1414/4885KDM4E 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.